Individual triptan selection in migraine attack therapy

Recent Patents on CNS Drug Discovery

Volumn 4, Issue 1, 2009, Pages 70-81

  Belvís, Robert ^a   Pagonabarraga, Javier ^a   Kulisevsky, Jaime ^a  

^a INSTITUT UNIVERSITARI DEXEUS   (Spain)

Author keywords

Analgesics; Ergot alkaloids; Migraine; Serotonin receptor agonist; Triptan

Indexed keywords

ALMOTRIPTAN; ANALGESIC AGENT; CYCLOOXYGENASE 2 INHIBITOR; DOPAMINE RECEPTOR BLOCKING AGENT; ELETRIPTAN; ERGOT ALKALOID; FORVEY; FROVATRIPTAN; NAPROXEN; NARATRIPTAN; NONSTEROID ANTIINFLAMMATORY AGENT; ORAL CONTRACEPTIVE AGENT; PARACETAMOL; PROPRANOLOL; RIZATRIPTAN; SEROTONIN; SUMATRIPTAN; SUMATRIPTAN SUCCINATE; TRIMEBUTINE; TRIPTAN DERIVATIVE; UNCLASSIFIED DRUG; ZOLMITRIPTAN; SEROTONIN AGONIST; TRYPTAMINE DERIVATIVE;

ANALGESIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ARTICLE; AUTOSOMAL DOMINANT INHERITANCE; CHEMOPROPHYLAXIS; CHEST TIGHTNESS; CLINICAL TRIAL; DIZZINESS; DRUG BIOAVAILABILITY; DRUG CONTRAINDICATION; DRUG COST; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG ELIMINATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG INDICATION; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; FATIGUE; HEAD AND NECK DISEASE; HUMAN; MIGRAINE; MIGRAINE AURA; NEUROGENIC INFLAMMATION; NEUROTRANSMISSION; PARESTHESIA; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REBOUND; THROAT TIGHTNESS; TREATMENT RESPONSE; VASOCONSTRICTION; VASODILATATION; ANIMAL; CLASSIFICATION; REVIEW;

ANIMALS; HUMANS; MIGRAINE DISORDERS; SEROTONIN AGONISTS; TRYPTAMINES;

EID: 62249193676     PISSN: 15748898     EISSN: None     Source Type: Journal    
DOI: 10.2174/157488909787002555     Document Type: Article

References (179)

1. Goadsby PT, Lipton RB, Ferrari MD. Migraine -current understanding and treatment. New England J Med 2002; 346: 257-270.
2. Headache classification subcommittee of the international headache society. The International Classification of Headache Disorders: 2nd edition. Cephalalgia 2004; 24 Suppl 1: 9-160.
3. Stewart WF, Lipton RB, Celentano DD, Reed ML. Prevalence of migraine headache in the United States. Relation to age, income, race, and other sociodemographic factors. JAMA 1992; 267: 64-69.
4. Rasmussen BK, Olesen J. Symptomatic and nonsymptomatic headaches in a general population. Neurology 1992; 42: 1225-1231.
5. Lipton RB, Stewart WF, von Korff M. Burden of migraine: Societal costs and therapeutic opportunities. Neurology 1997; 48(suppl 5): S4-9.
6. Fox AW, Davis RL. Migraine chronobiology. Headache 1998; 38: 436-441.
7. Hamelsky SW, Stewart WF, Lipton RB. Epidemiology of migraine. Current Pain and Headache Reports 2001; 5: 189-194.
8. Lipton RB, Stewart WF, Diamond S, et al. Prevalence and burden of migraine in the United States: Data from the American Migraine Study II. Headache 2001; 41: 646-657.
9. Lipton RB, Stewart WF, Scher AI. Epidemiology and economic impact of migraine. Curr Med Res Opin 2001(17 Suppl 1): S4-S12.
10. MacGregor EA, Brandes J, Eikermann A. Migraine prevalence and treatment patterns: The global migraine and zolmitriptan. Evaluation survey. Headache 2003; 43: 19-26
11. Stovner LJ, Zwart JA, Hagen K, Terwindt GM, Pascual J. Epidemiology of headache in Europe. Eur J Neurol 2006; 13: 333-345.
12. Hu XH, Markson LE, Lipton RB, et al. Burden of migraine in the United States: Disability and economic costs. Arch Intern Med 1999; 159: 813-818.
13. Auray JP. Socio-economic impact of migraine and headaches in France. CNS Drugs 2006; 20: 37-46
14. Stewart WF, Wood GC, Razzaghi H, Reed ML, Lipton RB. Work impact of migraine headaches. J Occup Environ Med 2008; 50: 736-745.
15. Hawkins K, Wang S, Rupnow M. Direct cost burden among insured US employees with migraine. Headache 2008; 48: 553-563
16. Weiller C, May A, Limmroth V, et al. Brainstem activation in spontaneous human migraine attacks. Nat Med 1995; 1: 658-660
17. Ray BS, Woolf HG. Experimental studies on headache: Pain sensitive structures of the head and their significance in headache. Arch Surg 1940; 41: 813-857.
18. Lashley KS. Patterns of cerebral integration indicated by the scotomas of migraine. Arch Neurol 1941; 46: 331-399.
19. Leao AAP. Spreading depression of activity in cerebral cortex. J Neurophysiol 1944; 7: 359-390.
20. Moskowitz MA, Nozaki K, Kraig RP. Neocortical spreading depression provokes the expression of c-fos protein-like immunoreactivity within trigeminal nucleus caudalis via trigeminovascular mechanisms. J Neurosci 1993; 13: 1167-1177.
21. Woods RP, Iacoboni M, Mazziotta JC. Bilateral spreading cerebral hypoperfusion during spontaneous migraine headache. N Engl J Med 1994; 331: 1689-1692.
22. Lauritzen M. Pathophysiology of the migraine aura. The spreading depression theory. Brain 1994; 117: 199-210.
23. Moskowitz MA. Neurogenic inflammation in the pathophysiology and treatment of migraine. Neurology 1993; 43: S16-S20.
24. Ferrari MD. Migraine. Lancet 1998; 351: 1043-1051.
25. Goadsby PJ, Edvinsson L, Ekman R. Release of vasoactive peptides in the extracerebral circulation of humans and the cat during activation of the trigeminovascular system. Ann Neurol 1988; 23: 193-196.
26. Ferrari MD, Saxena PR. On serotonin and migraine: A clinical and pharmacological review. Cephalalgia 1993; 13: 151-165.
27. Thomsen LL, Olesen J. Nitric oxide theory of migraine. Clin Neurosci 1998; 5: 28-33.
28. Thomsen LL, Olesen J. Nitric oxide in primary headaches. Curr Opin Neurol 2001; 14: 315-321.
29. Neeb L, Reuter U. Nitric oxide in migraine. CNS Neurol Disord Drug Targets 2007; 6: 258-264.
30. Stam AH, van den Maagdenberg AM, Haan J, Terwindt GM, Ferrari MD. Genetics of migraine: An update with special attention to genetic comorbidity. Curr Opin Neurol 2008; 21: 288-293.
31. Montagna P. Migraine genetics. Expert Rev Neurother 2008; 8: 1321-1330.
32. Pryse-Phillips WE, Dodick DW, Edmeads JG, et al. Guidelines for the nonpharmacologic management of migraine in clinical practice. Canadian Headache Society. CMAJ 1998; 159: 47-54.
33. Practice parameter: Evidence-based guidelines for migraine headache (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2000; 55: 754-763.
34. Members of the task force: Evers S, Afra J, Frese A, Goadsby PJ, Linde M, May A, Sandor PS. EFNS guideline on the drug treatment of migraine - report of an EFNS task force. Eur J Neurol 2006; 13: 560-572.
35. Ramadan NM. Current trends in migraine prophylaxis. Headache 2007; 47 [Suppl 1]: S52-S57.
36. Endres HG, Diener HC, Molsberger A. Role of acupuncture in the treatment of migraine. Expert Rev Neurother 2007; 7: 1121-1134.
37. Nestoriuc Y, Martin A. Efficacy of biofeedback for migraine: A meta-analysis. Pain 2007; 128: 111-127.
38. Göbel H, Heinze A, Niederberger U, Witt T, Zumbroich V. Efficacy of phenazone in the treatment of acute migraine attacks: A double-blind, placebo-controlled, randomized study. Cephalalgia 2004; 24: 888-893.
39. Tulunay FC, Ergun H, Gulmez SE, et al. The efficacy and safety of dipyrone (Novalgin) tablets in the treatment of acute migraine attacks: A double-blind, cross-over, randomized, placebocontrolled, multi-center study. Functional Neurol 2004; 19: 197-202.
40. Myllyla VV, Havanka H, Herrala L, et al. Tolfenamic acid rapid release versus sumatriptan in the acute treatment of migraine: Comparable effect in a double-blind, randomized, controlled, parallel-group study. Headache 1998; 38: 201-207.
41. Lipton RB, Baggish JS, Stewart WF, Codispoti JR, Fu M. Efficacy and safety of acetaminophen in the treatment of migraine: Results of a randomized, double-blind, placebocontrolled, population-based study. Arch Internal Med 2000; 160: 3486-3492.
42. Lipton RB, Stewart WF, Ryan RE, Saper J, Silberstein S, Sheftell F. Efficacy and safety of acetaminophen, aspirin, and caffeine in alleviating migraine headache pain- Three double-blind, randomized, placebo-controlled trials. Arch of Neurol 1998; 55: 210-217.
43. Diener H, Pfaffenrath V, Pageler L. The fixed combination of acetylsalicylic acid, paracetamol and caffeine is more effective than single substances and dual combination for the treatment of headache: A multicentre, randomized, double-blind, single-dose, placebocontrolled parallel group study. Cephalalgia 2005; 25: 776-787.
44. Goldstein J, Silberstein SD, Saper JR, Ryan RE Jr, Lipton RB. Acetaminophen, aspirin, and caffeine in combination versus ibuprofen for acute migraine: Results from a multicenter, doubleblind, randomized, parallel-group, single-dose, placebo-controlled study. Headache 2006; 46: 444-453.
45. Chabriat H, Joire JE, Danchot J, Grippon P, BousserMG. Combined oral lysine acetylsalicylate and metoclopramide in the acute treatment of migraine: A multicentre doubleblind placebocontrolled study. Cephalalgia 1994; 14: 297-300.
46. Nebe J, Heier M, Diener HC. Low-dose ibuprofen in selfmedication of mild to moderate headache: A comparison with acetylsalicylic acid and placebo. Cephalalgia 1995; 15: 531-535.
47. Tfelt-Hansen P, Henry P, Mulder LJ, Scheldewaert RG, Schoenen J, Chazot G. The effectiveness of combined oral lysine acetylsalicylate and metoclopramide compared with oral sumatriptan for migraine. Lancet 1995; 346: 923-926.
48. Diener HC, Bussone G, de Liano H, et al. Placebo-controlled comparison of effervescent acetylsalicylic acid, sumatriptan and ibuprofen in the treatment of migraine attacks. Cephalalgia 2004; 24: 947-954.
49. Johnson ES, Ratcliffe DM, Wilkinson M. Naproxen sodium in the treatment of migraine Cephalalgia 1985; 5: 5-10.
50. Treves TA, Streiffler M, Korczyn AD. Naproxen sodium versus ergotamine tartrate in the treatment of acute migraine attacks. Headache 1992; 32: 280-282.
51. Karachalios GN, Fotiadou A, Chrisikos N, Karabetsos A, Kehagioglou K. Treatment of acute migraine attack with diclofenac sodium: A double-blind study. Headache 1992; 32: 98-100.
52. Dahlöf C, Björkman R. Diclofenac-K (50 and 100 mg) and placebo in the acute treatment of migraine. Cephalalgia 1993; 13: 117-123.
53. The Diclofenac-K/Sumatriptan Migraine Study Group. Acute treatment of migraine attacks: Efficacy and safety of a nonsteroidal antiinflammatory drug, diclofenac potassium, in comparison to oral sumatriptan and placebo. Cephalalgia 1999; 9: 232-240.
54. Havanka-Kanniainen H. Treatment of acute migraine attack: Ibuprofen and placebo compared. Headache 1989; 29: 507-509.
55. Kloster R, Nestvold K, Vilming ST. A double-blind study of ibuprofen versus placebo in the treatment of acute migraine attacks. Cephalalgia 1992; 12: 169-171.
56. Suthisisang C, Poolsup N, Kittikulsuth W, Pudchakan P, Wiwatpanich P. Efficacy of low-dose ibuprofen in acute migraine treatment: Systematic review and meta-analysis. Ann Pharmacother 2007; 41: 1782-1791.
57. Allais G, De Lorenzo C, Airola G, Peano S, Benedetto C. Dexketoprofen trometamol in the treatment of acute migraine attack. Minerva Med 2000; 91: 153-159.
58. Meredith JT, Wait S, Brewer KL. A prospective double-blind study of nasal sumatriptan versus IV ketorolac in migraine. Am J Emerg Med 2003; 21: 173-175.
59. The Multinational Oral Sumatriptan and Cafergot Comparative Study Group. A randomized, doubleblind comparison of sumatriptan in the acute treatment of migraine. Eur Neurol 1991; 31: 314-322.
60. Christie S, Gobel H, Mateos V, Allen C, Vrijens F, Shivaprakash M, Rizatriptan-Ergotamine/Caffeine Preference Study Group. Crossover comparison of efficacy and preference for rizatriptan 10 mg versus ergotamine/caffeine in migraine. Eur Neurol 2003; 49: 20-29.
61. Diener HC, Jansen JP, Reches A, Pascual J, Pitei D, Steiner TJ, Eletriptan and Cafergot Comparative Study Group. Efficacy, tolerability and safety of oral eletriptan and ergotamine plus caffeine (Cafergot) in the acute treatment of migraine: A multicentre, randomized, double-blind, placebo-controlled comparison. Eur Neurol 2002; 47: 99-107.
62. Humphrey PP, Feniuk W, Perren MJ, Beresford IJ, Skingle M, Whalley ET. Serotonin and migraine. Ann NY Acad Sci 1990; 600: 587-598.
63. Pfaffenrath V, Cunin G, Sjonell G, Prendergast S. Efficacy and safety of sumatriptan tablets (25 mg, 50 mg, and 100 mg) in the acute treatment of migraine: Defining the optimum doses of oral sumatriptan. Headache 1998; 38: 184-190.
64. McCrory DC, Gray RN. Oral sumatriptan for acute migraine. Cochrane Database Syst Rev 2003; (3): CD002915.
65. Winner P, Landy S, Richardson M, Ames M. Early intervention in migraine with sumatriptan tablets 50 mg versus 100 mg: A pooled analysis of data from six clinical trials. Clin Ther 2005; 27: 1785-1794.
66. Diamond M, Hettiarachchi J, Hilliard B, Sands G, Nett R. Effectiveness of eletriptan in acute migraine: Primary care for excedrin nonresponders. Headache 2004; 44: 209-216.
67. Potrebic S, Ahn AH, Skinner K, Fields HL, Basbaum AI. Peptidergic nociceptors of both trigeminal and dorsal root ganglia express serotonin 1D receptors: Implications for the selective antimigraine action of triptans. J Neurosci 2003; 23: 10988-10997.
68. Wotherspoon G, Priestley JV. Expression of the 5-HT1B receptor by subtypes of rat trigeminal ganglion cells. Neuroscience 2000; 95: 465-471.
69. Longmore J, Razzaque Z, Shaw D, et al. Comparison of the vasoconstrictor effects of rizatriptan and sumatriptan in human isolated cranial arteries: Immunohistological demonstration of the involvement of 5-HT1B-receptors. Br J Clin Pharmacol 1998; 46: 577-582.
70. Tepper SJ, Rapoport AM, Sheftell FD. Mechanisms of action of the 5-HT1B/ 1D receptor agonists. Arch Neurol 2002; 59: 1084-1088.
71. Bonaventure P, Voorn P, Luyten WH, Jurzak M, Schotte A, Leysen JE. Detailed mapping of serotonin 5-HT1B and 5-HT1D receptor messenger RNA and ligand binding sites in guinea-pig brain and trigeminal ganglion: Clues for function. Neuroscience 1998; 82: 469-484.
72. Burstein R, Collins B, Jakubowski M. Defeating migraine pain with triptans: A race against the development of cutaneous allodynia. Ann Neurol 2004; 55: 19-26.
73. Burstein R, Jakubowski M. Analgesic triptan action in an animal model of intracranial pain: A race against the development of central sensitization. Ann Neurol 2004; 55: 27-36.
74. Ferrari MD, Goadsby PJ, Roon KI, Lipton RB. Triptans (serotonin, 5-HT1B/ 1D agonists) in migraine: Detailed results and methods of a meta-analysis of 53 trials. Cephalalgia 2002; 22: 633-658.
75. Gladstone JP, Dodick DW. Acute migraine: Which Triptan? Practical Neurology 2004; 4: 6-19.
76. Tfelt-Hansen P, Block G, Dahlöf C, et al. International Headache Society Clinical Trials Subcommittee. Guidelines for controlled trials of drugs in migraine: Second edition. Cephalalgia 2000; 20: 765-786.
77. Davies GM, Santanello N, Lipton R. Determinants of patient satisfaction with migraine therapy. Cephalalgia 2000; 20: 554-560.
78. Mathew NT. Naratriptan: A review. Expert Opin Investig Drugs 1999; 8: 687-95.
79. Spencer CM, Gunasekara NS, Hills C. Zolmitriptan: A review of its use in migraine. Drugs 1999; 58: 347-374.
80. Oldman AD, Smith LA, McQuay HJ, Moore RA. Rizatriptan for acute migraine. Cochrane Database Syst Rev 2001; (3): CD003221
81. Smith LA, Oldman AD, McQuay HJ, Moore RA. Eletriptan for acute migraine. Cochrane Database Syst Rev 2001; (3): CD003224.
82. Dowson AJ, Charlesworth B. Review of zolmitriptan and its clinical applications in migraine. Expert Opin Pharmacother 2002; 3: 993-1005.
83. Keam SJ, Goa KL, Figgitt DP. Almotriptan: A review of its use in migraine. Drugs 2002; 62: 387-414.
84. Ashcroft DM, Millson D. Naratriptan for the treatment of acute migraine: Meta-analysis of randomised controlled trials. Pharmacoepidemiol Drug Saf 2004; 13: 73-82.
85. Pascual J. A review of rizatriptan, a quick and consistent 5-HT1B/1D agonist for the acute treatment of migraine. Expert Opin Pharmacother 2004; 5: 669-677.
86. Poolsup N, Leelasangaluk V, Jittangtrong J, Rithlamlert C, Ratanapantamanee N, Khanthong M. Efficacy and tolerability of frovatriptan in acute migraine treatment: Systematic review of randomized controlled trials. J Clin Pharm Ther 2005; 30: 521-532.
87. McCormack PL, Keating GM. Eletriptan: A review of its use in the acute treatment of migraine. Drugs 2006; 66: 1129-1149.
88. Markus F, Mikko K. Frovatriptan review. Expert Opin Pharmacother 2007; 8: 3029-3033.
89. Chen LC, Ashcroft DM. Meta-analysis examining the efficacy and safety of almotriptan in the acute treatment of migraine. Headache 2007; 47: 1169-1177.
90. Chen LC, Ashcroft DM. Meta-analysis of the efficacy and safety of zolmitriptan in the acute treatment of migraine. Headache 2008; 48: 236-247.
91. Ferrari MD, Roon KI, Lipton RB, Goadsby PJ. Oral triptans (serotonin 5-HT(1B/1D) agonists) in acute migraine treatment: A meta-analysis of 53 trials. Lancet 2001; 358: 1668-1675.
92. Pascual J, Mateos V, Roig C, Sanchez-del-Rio M, Jiménez D. Marketed oral triptans in the acute treatment of migraine: A systematic review on efficacy and tolerability. Headache 2007; 47: 1152-1168.
93. Bates D, Ashford E, Dawson R, et al. Subcutaneous sumatriptan during the migraine aura. Neurology 1994; 44: 1587-1592.
94. Olesen J, Diener HC, Schoenen J, Hettiarachchi J. No effect of eletriptan administration during the aura phase of migraine. Eur J Neurol 2004; 11: 671-677.
95. Ferrari MD, James MH, Bates D, et al. Oral sumatriptan: Effect of a second dose, and incidence and treatment of headache recurrences. Cephalalgia 1994; 14: 330-338.
96. Geraud G, Keywood C, Senard JM. Migraine headache recurrence: Relationship to clinical, pharmacological, and pharmacokinetic properties of triptans. Headache 2003; 43: 376-388.
97. Tepper SJ, Rapoport AM. The triptans: A summary. CNS Drugs 1999; 12: 403-417.
98. Kramer MS, Matzura-Wolfe D, Polis A, et al. A placebo-controlled crossover study of rizatriptan in the treatment of multiple migraine attacks. Rizatriptan Multiple Attack Study Group. Neurology 1998; 51: 773-781.
99. Loder E, Brandes JL, Silberstein S, et al. Rizatriptan Protocol 060 Study Group. Preference comparison of rizatriptan ODT 10-mg and sumatriptan 50-mg tablet in migraine. Headache 2001; 41: 745-753.
100. Cady R, Crawford G, Ahrens S, et al. Rizatriptan-RPD Study Group. Long-term efficacy and tolerability of rizatriptan wafers in migraine. Med Gen Med 2001; 3: 1.
101. Dowson AJ, MacGregor EA, Purdy RA, Becker WJ, Green J, Levy SL. Zolmitriptan orally disintegrating tablet is effective in the acute treatment of migraine. Cephalalgia 2002; 22: 101-106.
102. Dowson AJ, Charlesworth BR. Patients with migraine prefer zolmitriptan orally disintegrating tablet to sumatriptan conventional oral tablet. Int J Clin Pract 2003; 57: 573-576.
103. Spierings EL, Rapoport AM, Dodick DW, Charlesworth B. Acute treatment of migraine with zolmitriptan 5 mg orally disintegrating tablet. CNS Drugs 2004; 18: 1133-1141.
104. Allen C. Rizatriptan: Clinical update. In: Humphrey P, Ferrari M, Olesen J, editors. The triptans: Novel drugs for migraine. New York: Oxford University Press, 2001; 199-205.
105. Sheftell FD, Dahlof CG, Brandes JL, Agosti R, Jones MW, Barrett PS. Two replicate randomized, double-blind, placebo-controlled trials of the time to onset of pain relief in the acute treatment of migraine with a fast-disintegrating/rapid-release formulation of sumatriptan tablets. Clin Ther 2005; 27: 407-417.
106. Visser WH, Ferrari MD, Bayliss EM, Ludlow S, Pilgrim AJ. Treatment of migraine attacks with subcutaneous sumatriptan: First placebo-controlled study. The Subcutaneous Sumatriptan International Study Group. Cephalalgia 1992; 12: 308-313.
107. Tfelt-Hansen P. Efficacy and adverse events of subcutaneous, oral, and intranasal sumatriptan used for migraine treatment: A systematic review based on number needed to treat. Cephalalgia 1998; 18: 532-538.
108. The Subcutaneous Sumatriptan International Study Group. Treatment of migraine attacks with sumatriptan. New England J Med 1991; 325: 316-321.
109. Charlesworth BR, Dowson AJ, Purdy A, Becker WJ, Boes-Hansen S, Färkkilä M. Speed of onset and efficacy of zolmitriptan nasal spray in the acute treatment of migraine: A randomised, doubleblind, placebo-controlled, dose-ranging study versus zolmitriptan tablet. CNS Drugs 2003; 17: 653-667.
110. Dodick D, Brandes J, Elkind A, Mathew N, Rodichok L. Speed of onset, efficacy and tolerability of zolmitriptan nasal spray in the acute treatment of migraine: A randomised, double-blind, placebocontrolled study. CNS Drugs 2005; 19: 125-136.
111. Pascual J, Navarro A, Caminero AB, Jurado C, Díaz-Insa S, Huerta M. Symptomatic treatment of migraine with zolmitriptan: Experience with 82 patients. Neurologia 2006; 21: 188-191.
112. Goadsby PJ, Yates R. Zolmitriptan intranasal: A review of the pharmacokinetics and clinical efficacy. Headache 2006; 46: 138-149.
113. Bellavance A, Belsey J. Triptan preference in acute migraine management: A retrospective review of patient records from a Canadian clinic population. Headache Care 2006; 3: 39-43.
114. Dowson AJ, Boes-Hansen S, Farkkila AM. Zolmitriptan nasal spray is fast-acting and highly effective in the acute treatment of migraine. Eur J Neurol 2000 7 (Suppl 3): 82.
115. Tepper SJ, Cochran A, Hobbs S, Woessner M. Sumatriptan suppositories for the acute treatment of migraine. Int J Clin Pract 1998; 52: 31-35.
116. Bertin L, Brion N, Färkkilä M, Göbel H, Wessely P. A dosedefining study of sumatriptan suppositories in the acute treatment of migraine. Int J Clin Pract 1999; 53: 593-598.
117. Jamieson DG. The safety of triptans in the treatment of patients with migraine. Am J Med 2002; 112: 135-140.
118. Fox AW. Comparative tolerability of oral 5-HT1B/1D agonists. Headache 2000; 40: 521-527.
119. Hall G, Brown M, Mo J, MacRae KD. Triptans in migraine: The risks of stroke, cardiovascular disease, and death in practice. Neurology 2004; 62: 563-568.
120. Velentgas P, Cole JA, Mo J, Sikes CR, Walker AM. Severe vascular events in migraine patients. Headache 2004; 44: 642-651.
121. Dahlöf CG, Mathew N. Cardiovascular safety of 5HT1B/1D agonists--is there a cause for concern? Cephalalgia 1998; 18: 539-545.
122. Visser WH, Jaspers NM, de Vriend RH, Ferrari MD. Chest symptoms after sumatriptan: A two-year clinical practice review in 735 consecutive migraine patients. Cephalalgia 1996; 16: 554-559.
123. Tfelt-Hansen P. Efficacy and adverse events of subcutaneous, oral, and intranasal sumatriptan used for migraine treatment: A systematic review based on number needed to treat. Cephalalgia 1998; 18: 532-538.
124. Källén B, Lygner PE. Delivery outcome in women who used drugs for migraine during pregnancy with special reference to sumatriptan. Headache 2001; 41: 351-356.
125. Olesen C, Steffensen FH, Sorensen HT, Nielsen GL, Olsen J. Pregnancy outcome following prescription for sumatriptan. Headache 2000; 40: 20-24.
126. Winner P. Triptans for migraine management in adolescents. Headache 2002; 42: 675-679
127. Evers S, Gralow I, Bauer B, et al. Sumatriptan and ergotamine overuse and drug-induced headache: A clinicoepidmiologic study. Clinical Neuropharmacology 1999; 22: 201-206.
128. Limmroth V, Kazarawa S, Fritsche G, Diener HC. Headache after frequent use of new serotonin agonists zolmitriptan and naratriptan. Lancet 1999; 353: 378.
129. Katsarava Z, Fritsche G, Muessig M, Diener HC, Limmroth V. Clinical features of withdrawal headache following overuse of triptans and other headache drugs. Neurology 2001; 57: 1694-1698.
130. Schulman EA, Cady RK, Henry D, et al. Effectiveness of sumatriptan in reducing productivity loss due to migraine: Results of a randomized, double-blind, placebo-controlled clinical trial. Mayo Clin Proc 2000; 75: 782-789.
131. Biddle AK, Shih YC, Kwong WJ. Cost-benefit analysis of sumatriptan tablets versus usual therapy for treatment of migraine. Pharmacotherapy 2000; 20: 1356-1364.
132. Caro G, Getsios D, Caro JJ, Raggio G, Burrows M, Black L. Sumatriptan: Economic evidence for its use in the treatment of migraine, the Canadian comparative economic analysis. Cephalalgia 2001; 21: 12-19.
133. Cady RK, Sheftell F, Lipton RB, Kwong WJ, O'Quinn S. Economic implications of early treatment of migraine with sumatriptan tablets. Clin Ther 2001; 23: 284-291.
134. Lofland JH, Kim SS, Batenhorst AS, et al. Cost-effectiveness and cost-benefit of sumatriptan in patients with migraine. Mayo Clin Proc 2001; 76: 1093-1101.
135. Zhang L, Hay JW. Cost-effectiveness analysis of rizatriptan and sumatriptan versus Cafergot in the acute treatment of migraine. CNS Drugs 2005; 19: 635-642.
136. Perfetto EM, Weis KA, Mullins CD, Subedi P, Healey PJ Sr. An economic evaluation of triptan products for migraine. Value Health 2005; 8: 647-655.
137. Mullins CD, Weis KA, Perfetto EM, Subedi PR, Healey PJ. Triptans for migraine therapy: A comparison based on number needed to treat and doses needed to treat. J Manag Care Pharm 2005; 11: 394-402.
138. Mullins CD, Subedi PR, Healey PJ, Sanchez RJ. Economic analysis of triptan therapy for acute migraine: A Medicaid perspective. Pharmacotherapy 2007; 27: 1092-1101.
139. Gracia-Naya M, Rejas GJ, Latorre JA, González GP. Economic evaluation of acute migraine attack treatment with triptans in Spain. Neurologia 2005; 20: 121-132.
140. Ramsberg J, Henriksson M. The cost-effectiveness of oral triptan therapy in Sweden. Cephalalgia 2007; 27: 54-62.
141. Adelman JU, Reeder CE, Steadman S, Goldfarb SD. Economic comparison of oral triptans for management of acute migraine: Implications for managed care. Am J Manag Care 2002; 8(3 Suppl): S80-S84.
142. Kelman L, Von Seggern RL. Using patient-centered endpoints to determine the cost-effectiveness of triptans for acute migraine therapy. Am J Ther 2006; 13: 411-417.
143. Mannix LK, Adelman JU, Goldfarb SD, et al. Almotriptan versus sumatriptan in migraine treatment: Direct medical costs of managing adverse chest symptoms. Am J Manag Care 2002; 8(3 Suppl): S94-S101.
144. Wang JT, Barr CE, Goldfarb SD. Impact of chest pain on cost of migraine treatment with almotriptan and sumatriptan. Headache 2002; 42(Suppl 1): 38-43.
145. Wang JT, Barr CE, Torigoe Y, et al. Cost savings in migraine associated with less chest pain on new triptan therapy. Am J Manag Care 2002; 8(3 Suppl): S102-S107.
146. Adelman JU, Belsey J. Meta-analysis of oral triptan therapy for migraine: Number needed to treat and relative cost to achieve relief within 2 hours. J Manag Care Pharm 2003; 9: 45-52.
147. Gori S, Morelli N, Acuto G, Caiola F, Iudice A, Murri L. A pharmacoeconomic evaluation of oral triptans in the treatment of migraine in Italy. Minerva Med 2006; 97: 467-477.
148. Dodik DW. Triptan Nonresponder Studies: Implications for clinical practice. Headache 2005; 45: 156-162
149. Thomsen LL, Dixon R, Lassen LH, et al. 311C90 (zolmitriptan), a novel centrally and peripheral acting oral 5-hydroxytryptamine-1D agonist: A comparison of its absorption during a migraine attack and in a migrainefree period. Cephalalgia 1996; 16: 270-275.
150. Tfelt-Hansen P, Edvinsson L. Pharmacokinetic and pharmacodynamic variability as possible causes for different drug responses in migraine. A comment. Cephalalgia 2007; 27: 1091-1093.
151. Lacey LF, Hussey EK, Fowler PA. Single dose pharmacokinetics of sumatriptan in healthy volunteers. Eur J Clin Pharmacol 1995; 47: 543-548.
152. Seaber E, On N, Dixon RM, et al. The absolute bioavailability and metabolic disposition of the novel antimigraine compound zolmitriptan (311C90). Br J Clin Pharmacol 1997; 43: 579-587.
153. Freitag F, Diamond M, Diamond S, Janssen I, Rodgers A, Skobieranda F. Efficacy and tolerability of coadministration of rizatriptan and acetaminophen vs rizatriptan or acetaminophen alone for acute migraine treatment. Headache 2008; 48: 921-930.
154. Sumatriptan and naproxen sodium for the acute treatment of migraine. Headache 2005; 45: 983-991.
155. Floyd, A.G., Navy, C.C., Goodson, G.W.: US20070184109A1 (2007).
156. Winner P, Cady RK, Ruoff GE, et al. Twelve-month tolerability and safety of sumatriptan-naproxen sodium for the treatment of acute migraine. Mayo Clin Proc 2007; 82: 61-68.
157. Brandes JL, Kudrow D, Stark SR, et al. Sumatriptan-naproxen for acute treatment of migraine: A randomized trial. JAMA 2007; 297: 1443-1154.
158. Smith T, Blumenthal H, Diamond M, et al. Sumatriptan/Naproxen sodium for migraine: Efficacy, health related quality of life, and satisfaction outcomes. Headache 2007; 47: 683-692.
159. Krymchantowski AV, Jevoux Cda C. The experience of combining agents, specially triptans and non steroidal anti-inflammatory drugs, for the acute treatment of migraine - a review. Recent Patents CNS Drug Discov 2007; 2: 141-144.
160. Landy S, DeRossett SE, Rapoport A, et al. Two double-blind, multicenter, randomized, placebo-controlled, single-dose studies of sumatriptan/naproxen sodium in the acute treatment of migraine: Function, productivity, and satisfaction outcomes. Med Gen Med 2007; 9: 53.
161. Silberstein SD, Mannix LK, Goldstein J, et al. Multimechanistic (sumatriptan-naproxen) early intervention for the acute treatment of migraine. Neurology 2008; 71: 114-121.
162. Krymchantowski AV, Filho PF, Bigal ME. Rizatriptan vs rizatriptan plus trimebutine for the acute treatment of migraine: A double-blind, randomized, cross-over, placebo-controlled study. Cephalalgia 2006; 26: 871-874
163. Krymchantowski, A.V.: US20080081798A1 (2008).
164. Silberstein S, Tepper S, Brandes J, et al. Randomized, placebocontrolled trial of rofecoxib in the acute treatment of migraine. Neurology 2004; 62: 1552-1557.
165. Saper J, Dahlof C, So Y, et al. Rofecoxib Protocol 162 Study Group. Rofecoxib in the acute treatment of migraine: A randomized controlled clinical trial. Headache 2006; 46: 264-275.
166. Misra UK, Jose M, Kalita J. Rofecoxib versus ibuprofen for acute treatment of migraine: A randomised placebo controlled trial. Postgrad Med J 2004; 80: 720-723.
167. Loo CY, Tan HJ, Teh HS, Raymond AA. Randomised, open label, controlled trial of celecoxib in the treatment of acute migraine. Singapore Med J 2007; 48(9): 834-839.
168. Krymchantowski AV, Bigal ME. Rizatriptan versus rizatriptan plus rofecoxib versus rizatriptan plus tolfenamic acid in the acute treatment of migraine. BMC Neurol 2004; 4: 10.
169. Krymchantowski AV, Barbosa JS. Rizatriptan combined with rofecoxib vs rizatriptan for the acute treatment of migraine: An open label pilot study. Cephalalgia 2002; 22: 309-312.
170. Schulman EA, Dermott KF. Sumatriptan plus metoclopramide in triptan-nonresponsive migraineurs. Headache 2003; 43: 729-733. [170] Maichle, W.R., Whatley, C.L., Reiner, G., Reiner, A.: WO2007127207A2 (2007).
171. Goldstein J, Dahlöf CG, Diener HC, et al. Alniditan in the acute treatment of migraine attacks: A subcutaneous dose-finding study. Subcutaneous Alniditan Study Group. Cephalalgia 1996; 16: 497-502
172. Diener HC, Tfelt-Hansen P, de Beukelaar F, et al. Study Group. The efficacy and safety of sc alniditan vs sc sumatriptan in the acute treatment of migraine: A randomized, double-blind, placebocontrolled trial. Cephalalgia 2005; 21: 672-679.
173. Knight YE, Edvinsson L, Goadsby PJ. Blockade of calcitonin generelated peptide release after superior sagittal sinus stimulation in cat: A comparison of avitriptan and CP122,288. Neuropeptides 1999; 33: 41-46.
174. Sharma A, Jusko WJ, Fulmor IE, Norton J, Uderman HD, Salazar DE. Pharmacokinetics and pharmacodynamics of avitriptan during intravenous administration in healthy subjects. J Clin Pharmacol 1999; 39: 685-694.
175. Muñoz-Islas E, Gupta S, Jiménez-Mena LR, et al. Donitriptan, but not sumatriptan, inhibits capsaicin-induced canine external carotid vasodilatation via 5-HT1B rather than 5-HT1D receptors. Br J Pharmacol 2006; 149: 82-91.
176. Létienne R, Blanchet JC, Sole E, John GW, Le Grand B. Donitriptan decreases jugular venous oxygen saturation in rats in the absence of cranial vasoconstriction: An overlooked mechanism of antimigraine action? J Pharmacol Exp Ther 2005; 315: 849-857.
177. Tfelt-Hansen P. Triptans vs other drugs for acute migraine. Are there differences in efficacy? A comment. Headache 2008; 48: 601-605.
178. Hettiarachchi, J., Reza, I.H.M., Sikes, C.R.: US20070191462A1 (2007).
179. Tepper SJ, Stillman MJ. Clinical and preclinical rationale for CGRP-receptor antagonists in the treatment of migraine. Headache 2008; 48: 1259-1268.